The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Nearly one in five women worldwide are now living with obesity
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
This marks the second consecutive year that Juneja has made a personal contribution towards supporting the armed forces
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The company plans to collaborate with European medical centres to expand adoption of its robotic microsurgery platform
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
Company handles 20,000+ AI-driven calls and chats daily as it scales agentic AI systems across healthcare workflows
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
